CLOs on the Move

OptionCare

www.optioncare.com

 
Option Care is a leading provider of home and alternate treatment site infusion services. With a staff of more than 1,700 clinical experts – including specially trained infusion nurses, infusion pharmacists and registered dietitians – Option Care treats patients with a wide range of acute and chronic conditions. Comprehensive therapy management programs are offered for patients with nutrition disorders, bleeding disorders and heart failure, as well as those needing immunoglobulin (IG) therapy and anti-infective therapy. Option Care is able to provide services to 92% of the nation`s population through more than 90 infusion pharmacies and 100 alternate treatment ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion
  • www.optioncare.com
  • 485 E Half Day Rd Ste 300
    Buffalo Grove, IL USA 60089
  • Phone: 800.879.6137

Executives

Name Title Contact Details
Cliff Berman
Senior Vice President - General Counsel and Corporate Secretary Profile

Similar Companies

Cansortium

Cansortium Holdings utilizes a unique combination of capital and expertise in making strategic investments to help launch mature and professional cannabis markets. As global regulations evolve, Consortium Holdings is well-positioned to expand its presence in the U.S. and Puerto Rico.

Assistek

Assistek is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

P.E.C.S.

P.E.C.S. is a Canovanas, PR-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Akcea Therapeutics

Akcea Therapeutics is a development and commercialization company focused on helping patients with serious diseases. Our priority is to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize our products on a global basis. We are driven by knowing that patients depend on us. An affiliate of Ionis Pharmaceuticals and based in Kendall Square, Cambridge, Massachusetts, Akcea was founded with a robust portfolio of development-stage drugs covering multiple targets and disease states using advanced antisense therapeutics. Akcea is derived from the Greek word for value and worth. Something that has akcea (αξία) is not common, but precious and rare. Our name supports the value we are creating for physicians, patients and their families, and other key stakeholders as we seek to commercialize a robust portfolio of development-stage, advanced, antisense therapies for serious cardiometabolic lipid disorders. Our immediate focus is to drive our clinical programs forward through development to commercialization while building on the Isis standards of excellence.